Inositol has a beneficial effect in the management of polycystic ovary syndrome: Special data for Libyan patients

Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. This study aims to overview of PCOS pathophysiology and therapy, focusing particularly on the therapeutic role of inositol, followed by an evaluation of a specific clinical intervention in Libyan patients. The study assessed the effects of inositol in combination with metformin on hormonal and metabolic parameters in Libyan patients with PCOS. This study was conducted at the Tripoli Infertility Treatment Hospital between August and October 2025. The study included 80 women diagnosed with infertility associated with PCOS according to the Rotterdam criteria, with 42 participants having complete data. Participants were divided into two groups who received treatment for three months: 21 patients received myo-inositol plus d-chiro-inositol, and 21 patients received inositol combined with metformin. The findings showed a reduction in LH, LH/FSH ratio, AMH, HOMA-IR, and HbA1c, along with increased estradiol. FSH, prolactin, and TSH remained unchanged. No differences were observed between myo-inositol and combination therapy. This study suggests that inositol is an effective supplement therapy for Libyan patients with PCOS, improving ovarian function and metabolic health. The benefits are likely mediated by enhanced insulin sensitivity, which helps restore gonadotropin balance and alleviate symptoms.